Generate Biomedicines (NASDAQ:GENB) Trading Up 5.9% – Time to Buy?

Generate Biomedicines Inc (NASDAQ:GENB) shares traded up 5.9% on Wednesday . The company traded as high as $12.70 and last traded at $12.68. 466,795 shares changed hands during trading, a decline of 14% from the average session volume of 541,836 shares. The stock had previously closed at $11.97.

Analysts Set New Price Targets

A number of research firms recently commented on GENB. Wall Street Zen cut Generate Biomedicines from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Piper Sandler began coverage on Generate Biomedicines in a research report on Tuesday, March 24th. They set an “overweight” rating and a $24.00 price objective for the company. Zacks Research raised shares of Generate Biomedicines to a “hold” rating in a research note on Wednesday, March 25th. Guggenheim assumed coverage on shares of Generate Biomedicines in a research report on Tuesday, March 24th. They set a “buy” rating and a $30.00 price target for the company. Finally, Cantor Fitzgerald assumed coverage on Generate Biomedicines in a report on Tuesday, March 24th. They set an “overweight” rating for the company. Six equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $25.40.

Generate Biomedicines Price Performance

The stock’s 50-day moving average price is $13.12.

Generate Biomedicines (NASDAQ:GENB) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.59).

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.